Full-Time

Executive Director

Multiple Teams

Deadline 8/24/26
Merck

Merck

10,001+ employees

Pharmaceutical company developing medicines and vaccines

Compensation Overview

$255.8k - $402.7k/yr

+ Annual bonus + Long-term incentive

No H1B Sponsorship

Boston, MA, USA + 3 more

More locations: North Wales, PA, USA | South San Francisco, CA, USA | Rahway, NJ, USA

Hybrid

Hybrid work arrangement; relocation is domestic.

Master's, PhD

Category
Biology & Biotech (1)
Required Skills
Biostatistics

Get referred to Merck

See people who can refer or advise you

Requirements
  • An advanced scientific or healthcare degree: PhD or PharmD with at least 10 years of oncology drug development experience, or a Master's degree in life sciences with 15 years of oncology drug development experience.
  • Significant experience in oncology drug development across multiple phases of clinical development.
  • Deep expertise in Clinical Science, Clinical Development, and execution of global clinical programs.
  • Experience supporting regulatory submissions, health authority interactions, and late-stage development activities.
  • Proven leadership experience in large, matrixed organizations through multiple levels of management.
  • Demonstrated success developing talent, building leadership capability, and creating high-performing teams.
  • Advanced analytics, artificial intelligence, clinical development, clinical sciences, cross-functional leadership, executive leadership, global clinical studies, innovation, matrix leadership, oncology, oncology drug development, regulatory submissions, strategic leadership, and talent development.
Responsibilities
  • Hold accountability for portfolio delivery from the Clinical Science perspective, including prioritization, resource alignment, and support for key development milestones across studies, programs, and assets.
  • Provide strategic oversight for a portfolio of oncology assets across multiple therapeutic areas and stages of development.
  • Partner with Therapeutic Area Heads and leaders across Clinical Operations, Regulatory Affairs, Biostatistics and Data Management, Drug Safety and Pharmacovigilance, Translational Medicine, and Medical Affairs to drive development strategy execution and delivery of key portfolio milestones.
  • Ensure Clinical Science contributions support development plans, regulatory submissions, health authority interactions, and lifecycle management activities.
  • Apply Clinical Science expertise to inform therapeutic area and portfolio strategy across evolving science, treatment trends, competitive landscape, and regulatory considerations.
  • Optimize allocation of Clinical Science resources and associated budgets across a complex and evolving portfolio to align with business priorities and organizational objectives.
  • Serve as a senior escalation point for scientific and resource-related issues, enabling effective and timely resolution.
  • Establish and sustain high standards for scientific rigor, clinical science quality, medical data review, study oversight, and regulatory readiness across the portfolio.
  • Drive consistency in clinical science practices, study execution, and data interpretation across therapeutic areas and development programs.
  • Foster proactive risk identification, mitigation, inspection readiness, and continuous quality improvement.
  • Advance innovative approaches to medical data review, signal detection, study oversight, and evidence-based decision-making.
  • Champion adoption of artificial intelligence-enabled, digital, and technology-driven capabilities that enhance Clinical Science productivity, quality, efficiency, and effectiveness.
  • Identify opportunities to leverage advanced analytics, artificial intelligence, automation, and digital solutions to improve decision-making, strengthen study oversight, and streamline workflows.
  • Drive modernization of clinical data review through innovative approaches that enhance insight generation and support timely, informed decisions.
  • Foster innovation, experimentation, continuous learning, and responsible implementation of emerging technologies.
  • Partner with cross-functional stakeholders to define, develop, and implement scalable capabilities that support future organizational needs and long-term business success.
  • Lead, coach, and develop a high-performing Clinical Science organization.
  • Guide, develop, and hold accountable leaders at multiple levels within the Clinical Science organization.
  • Build organizational capability through talent planning, succession management, leadership development, and career growth strategies.
  • Create an inclusive environment that promotes engagement, psychological safety, accountability, collaboration, and continuous development.
  • Develop future leaders by mentoring Clinical Scientists and Clinical Science people leaders.
  • Ensure leaders provide effective coaching, feedback, performance development, and career support for their teams.
  • Contribute to the development and execution of Clinical Science strategy, priorities, and long-term organizational objectives.
  • Lead initiatives related to organizational design, workforce planning, and resource optimization to support evolving portfolio and business needs.
  • Develop and implement scalable operating models that balance portfolio execution, organizational effectiveness, employee development, and talent retention.
  • Lead cross-functional initiatives that improve efficiency, effectiveness, innovation, and organizational health.
  • Represent Clinical Science in governance forums, leadership discussions, and strategic planning activities.
  • Shape functional and enterprise priorities through leadership engagement, cross-functional partnerships, and influence across organizational boundaries.
  • Develop decision criteria considering cost, benefits, risks, timing, and buy-in, and select strategies most likely to succeed.
  • Identify key tasks and resources needed to achieve strategic objectives.
  • Ensure those responsible for implementing strategic initiatives have role clarity, accountability, direction, and authority to act consistently with organizational values.
  • Remove development barriers, advocate for individuals to create development opportunities, provide guidance and positive models, seek suggestions for improving performance, and collaboratively create development plans.
  • Create momentum for organizational, process, and product or service improvements by providing resources and direction, breaking down barriers to change, and recognizing contributions to change efforts.
Desired Qualifications
  • Experience in the therapeutic areas of Thoracic, Lung, Head & Neck, and Gastrointestinal oncology.
  • Familiarity with, or interest in, emerging artificial intelligence, advanced analytics, and digital capabilities applicable to clinical development.

Merck is a global healthcare company that develops medicines, vaccines, and animal health products. It advances long-term health by conducting research and development to create new treatments for diseases such as cardiovascular disease, diabetes, and cancer, then brings these medicines to patients, healthcare professionals, and institutions worldwide. The company’s products work by undergoing scientific discovery, clinical testing, and regulatory approval before being manufactured and sold or distributed through patient assistance programs. What sets Merck apart is its large, diversified portfolio across human medicines, vaccines, and animal health, along with a strong emphasis on R&D, global reach, and support services like Merck Connect and Merck Manuals that provide professional resources. Merck’s goal is to tackle major health threats by applying science to discover and deliver therapies that improve patient outcomes and public health across the globe.

Company Size

10,001+

Company Stage

IPO

Headquarters

Kenilworth, Illinois

Founded

1891

Get referred to Merck

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $16.6 billion, up 5% year over year.
  • INTerpath-001 met RFS and DMFS endpoints on August 19, 2026.
  • Merck will present data and pursue filings, expanding intismeran into more tumors.

What critics are saying

  • Keytruda patents start expiring in 2028, exposing Merck to biosimilar erosion.
  • Gardasil layoffs in North Carolina began May 2026, signaling demand weakness and cost pressure.
  • If intismeran disappoints beyond melanoma, Merck loses its clearest post-Keytruda replacement.

What makes Merck unique

  • Keytruda generated $8.37 billion in Q2 2026, powering Merck’s oncology scale.
  • Merck’s August 19, 2026 intismeran win validates individualized mRNA oncology manufacturing.
  • Merck split Human Health on February 23, 2026, sharpening oncology focus.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

-20%

1 year growth

-20%

2 year growth

-20%
Yahoo Finance
Aug 21st, 2026
Musk backs mRNA potential as Moderna and Merck trial shows cancer vaccine breakthrough

Elon Musk said mRNA technology has "tremendous promise for curing diseases" despite what he termed its "obvious misuse during Covid". The Tesla chief executive officer suggested artificial RNA essentially makes curing diseases a software problem. Musk's comments came as Moderna and Merck announced positive Phase 3 results for an individualised mRNA cancer vaccine. The treatment showed significant improvement in recurrence-free and metastasis-free survival in melanoma patients when combined with Merck's Keytruda. This marks the first successful late-stage trial of its kind. Musk has previously promoted artificial intelligence as a path to transforming healthcare. In June, he said advances in synthetic RNA could potentially "cure almost anything".

Yahoo Finance
Aug 20th, 2026
Merck takes $3.8M stake in AI vaccine developer Evaxion after licensing bacterial candidate

Merck & Company disclosed holding 1,214,126 shares of AI immunology firm Evaxion A/S in a regulatory filing on 10 August. Evaxion shares rose 2% to $3.17 following the announcement. The position follows Merck's September 2025 decision to in-license EVX-B3, Evaxion's discovery-stage vaccine candidate targeting an undisclosed bacterial pathogen. Argus raised its price target on Merck from $130 to $145 on 11 August, citing regulatory approvals and pipeline depth. Merck reported Q2 2026 revenue of $16.6 billion, up 5% year-over-year, driven by $8.4 billion from KEYTRUDA. Evaxion reported zero revenue in Q1 2026 with a net loss of $3.6 million. Hedge fund holdings in Merck fell from 100 funds in Q4 2025 to 98 in Q1 2026.

Yahoo Finance
Aug 20th, 2026
Merck dips 0.5% after 12.6% surge on positive cancer-vaccine trial results

Merck shares dipped approximately 0.5% to $151.39 on Thursday following a 12.6% surge the previous day, reaching a record close. The pharmaceutical company's stock jumped after positive results from a Phase 3 trial testing a personalized melanoma vaccine developed with Moderna. The 1,137-patient study met its primary endpoints for recurrence-free survival and distant-metastasis-free survival. The trial compared Keytruda alone against Keytruda plus intismeran in patients with surgically removed high-risk melanoma, with no new safety concerns identified. Merck and Moderna are also testing the vaccine platform in lung, bladder, kidney, pancreatic and stomach cancers. Keytruda generated approximately $8.4 billion in second-quarter sales, representing roughly half of Merck's revenue. The stock now trades 26.28% above its estimated fair value of $119.88.

Yahoo Finance
Aug 20th, 2026
Merck surges 12.6% as personalised cancer vaccine beats standard melanoma treatment

Merck announced its personalised cancer vaccine combined with immunotherapy Keytruda significantly improved outcomes for melanoma patients in a Phase 3 trial. The 135-year-old drugmaker's stock jumped 12.6% on 19 August following the news. The trial tested intismeran autogene, developed with Moderna, alongside Keytruda in patients with surgically removed stage IIB through IV melanoma. Patients receiving the combination stayed cancer-free longer and experienced delayed cancer spread compared to those on Keytruda alone. The treatment uses mRNA technology tailored to each patient's tumour mutations, training the immune system to target up to 34 specific genetic changes. It marks the first time an individualised cancer vaccine has shown positive results in late-stage testing. Keytruda generated $8.4 billion in second-quarter sales, representing over 50% of Merck's quarterly revenue.

Yahoo Finance
Aug 20th, 2026
Merck melanoma vaccine trial beats expectations, but RBC downgrades stock over $30B Keytruda patent cliff

Merck's promising Phase 3 melanoma trial results drew mixed reactions from Wall Street. RBC Capital downgraded Merck to 'Sector Perform' from 'Outperform', calling the stock's $150 valuation "unprecedented" for a company facing major patent expiry in two years. Key patents covering Keytruda, Merck's best-selling cancer drug that generated over $30 billion in 2025 and represents nearly half of its revenue, begin expiring in 2028. RBC said further gains would require the pipeline to exceed already elevated expectations. However, BofA maintained its 'Buy' rating, raising its price target to $166, citing confidence that Merck can offset Keytruda's patent challenges. BMO Capital raised its target to $170, noting the trial could represent $5.6 billion in potential peak revenue. The trial tested Intismeran Autogene with Keytruda in melanoma patients, significantly extending time without recurrence.